Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus

Antiviral Research

Volumn 139, Issue , 2017, Pages 49-58

  Lee, Hyun ^a   Ren, Jinhong ^b   Nocadello, Salvatore ^c   Rice, Amy J ^b   Ojeda, Isabel ^b   Light, Samuel ^c   Minasov, George ^c   Vargas, Jason ^b   Nagarathnam, Dhanapalan ^d   Anderson, Wayne F ^c   Johnson, Michael E ^a  

^a Novalex Therapeutics   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d DNSK International LLC   (United States)

Author keywords

apo ZIKV NS2B NS3pro structure; NS2B NS3 serine protease; Small molecule inhibitor; Zika flavivirus

Indexed keywords

ANTIVIRUS AGENT; BENZOTHIAZOLE; CHYMOTRYPSIN; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; SERINE PROTEINASE INHIBITOR; SULFONAMIDE; TRYPSIN; SERINE PROTEINASE; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DISSOCIATION CONSTANT; DRUG CONFORMATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME KINETICS; EQUILIBRIUM CONSTANT; HIGH THROUGHPUT SCREENING; IC50; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; SURFACE PLASMON RESONANCE; VIRUS REPLICATION; ZIKA VIRUS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; KINETICS; METABOLISM;

ANTIVIRAL AGENTS; DRUG DISCOVERY; INHIBITORY CONCENTRATION 50; KINETICS; PROTEIN CONFORMATION; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; SURFACE PLASMON RESONANCE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION; ZIKA VIRUS;

EID: 85007556298     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.12.016     Document Type: Article

References (64)

1. Aguirre, S., Maestre, A.M., Pagni, S., Patel, J.R., Savage, T., Gutman, D., Maringer, K., Bernal-Rubio, D., Shabman, R.S., Simon, V., Rodriguez-Madoz, J.R., Mulder, L.C., Barber, G.N., Fernandez-Sesma, A., DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathogens, 8, 2012, e1002934.
2. Aleshin, A.E., Shiryaev, S.A., Strongin, A.Y., Liddington, R.C., Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Science A Publ. Protein Soc. 16 (2007), 795–806.
3. Anderson, W.F., Structural genomics and drug discovery for infectious diseases. Infect. Disord. Drug Targets 9 (2009), 507–517.
4. Bhakat, S., Karubiu, W., Jayaprakash, V., Soliman, M.E., A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses. Eur. J. Med. Chem. 87 (2014), 677–702.
5. Cabarcas-Montalvo, M., Maldonado-Rojas, W., Montes-Grajales, D., Bertel-Sevilla, A., Wagner-Dobler, I., Sztajer, H., Reck, M., Flechas-Alarcon, M., Ocazionez, R., Olivero-Verbel, J., Discovery of antiviral molecules for dengue: in silico search and biological evaluation. Eur. J. Med. Chem. 110 (2016), 87–97.
6. Chan, J.F., Choi, G.K., Yip, C.C., Cheng, V.C., Yuen, K.Y., Zika fever and congenital Zika syndrome: an unexpected emerging arboviral disease. J. Infect., 72, 2016.
7. Chen, X., Yang, K., Wu, C., Chen, C., Hu, C., Buzovetsky, O., Wang, Z., Ji, X., Xiong, Y., Yang, H., Mechanisms of activation and inhibition of Zika virus NS2B-NS3 protease. Cell Res. 26 (2016), 1260–1263.
8. Chu, J.J., Lee, R.C., Ang, M.J., Wang, W.L., Lim, H.A., Wee, J.L., Joy, J., Hill, J., Brian Chia, C.S., Antiviral activities of 15 dengue NS2B-NS3 protease inhibitors using a human cell-based viral quantification assay. Antivir. Res. 118 (2015), 68–74.
9. Cohen, J., Infectious disease. The race for a Zika vaccine is on. Science (New York, N.Y.) 351 (2016), 543–544.
10. Cunha, M.S., Esposito, D.L., Rocco, I.M., Maeda, A.Y., Vasami, F.G., Nogueira, J.S., de Souza, R.P., Suzuki, A., Addas-Carvalho, M., Barjas-Castro Mde, L., Resende, M.R., Stucchi, R.S., Boin Ide, F., Katz, G., Angerami, R.N., da Fonseca, B.A., First Complete Genome Sequence of Zika Virus (Flaviviridae, Flavivirus) from an Autochthonous Transmission in Brazil. 2016 Genome announcements 4.
11. Deng, J., Li, N., Liu, H., Zuo, Z., Liew, O.W., Xu, W., Chen, G., Tong, X., Tang, W., Zhu, J., Zuo, J., Jiang, H., Yang, C.G., Li, J., Zhu, W., Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping. J. Med. Chem. 55 (2012), 6278–6293.
12. Dick, G.W., Kitchen, S.F., Haddow, A.J., Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 46 (1952), 509–520.
13. Dyer, O., Zika virus spreads across Americas as concerns mount over birth defects. BMJ Clin. Res. Ed., 351, 2015, h6983.
14. Emsley, P., Cowtan, K., Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D. Biol. Crystallogr. 60 (2004), 2126–2132.
15. Erbel, P., Schiering, N., D'Arcy, A., Renatus, M., Kroemer, M., Lim, S.P., Yin, Z., Keller, T.H., Vasudevan, S.G., Hommel, U., Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 13 (2006), 372–373.
16. Faye, O., Freire, C.C., Iamarino, A., Faye, O., de Oliveira, J.V., Diallo, M., Zanotto, P.M., Sall, A.A., Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS Negl. Trop. Dis., 8, 2014, e2636.
17. Gatherer, D., Kohl, A., Zika virus: a previously slow pandemic spreads rapidly through the Americas. J. Gen. Virol. 97 (2016), 269–273.
18. Gould, E.A., Solomon, T., Pathogenic flaviviruses. Lancet (London, England) 371 (2008), 500–509.
19. Gulland, A., WHO warns European countries to be on alert for Zika. BMJ Clin. Res. Ed., 352, 2016, i753.
20. Halfon, P., Locarnini, S., Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 55 (2011), 192–206.
21. Hammamy, M.Z., Haase, C., Hammami, M., Hilgenfeld, R., Steinmetzer, T., Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease. ChemMedChem 8 (2013), 231–241.
22. Imperato, P.J., The convergence of a virus, mosquitoes, and human travel in globalizing the Zika epidemic. J. Community Health, 41, 2016.
23. Kuno, G., Chang, G.J., Tsuchiya, K.R., Karabatsos, N., Cropp, C.B., Phylogeny of the genus flavivirus. J. Virol. 72 (1998), 73–83.
24. Lai, H., Dou, D., Aravapalli, S., Teramoto, T., Lushington, G.H., Mwania, T.M., Alliston, K.R., Eichhorn, D.M., Padmanabhan, R., Groutas, W.C., Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases. Bioorg. Med. Chem. 21 (2013), 102–113.
25. Lai, H., Sridhar Prasad, G., Padmanabhan, R., Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro. Antivir. Res. 97 (2013), 74–80.
26. Lee, H., Zhu, T., Patel, K., Zhang, Y.Y., Truong, L., Hevener, K.E., Gatuz, J.L., Subramanya, G., Jeong, H.Y., Uprichard, S.L., Johnson, M.E., High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes. PLoS One, 8, 2013, e75144.
27. Lei, J., Hansen, G., Nitsche, C., Klein, C.D., Zhang, L., Hilgenfeld, R., Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. Science 353 (2016), 503–505.
28. Lei, J., Hilgenfeld, R., Structural and mutational analysis of the interaction between the Middle-East respiratory syndrome coronavirus (MERS-CoV) papain-like protease and human ubiquitin. Virol. Sin., 31, 2016.
29. Li, L., Basavannacharya, C., Chan, K.W., Shang, L., Vasudevan, S.G., Yin, Z., Structure-guided discovery of a novel non-peptide inhibitor of Dengue virus NS2B-NS3 protease. Chem. Biol. Drug Des. 86 (2015), 255–264.
30. Lim, S.P., Wang, Q.Y., Noble, C.G., Chen, Y.L., Dong, H., Zou, B., Yokokawa, F., Nilar, S., Smith, P., Beer, D., Lescar, J., Shi, P.Y., Ten years of dengue drug discovery: progress and prospects. Antivir. Res. 100 (2013), 500–519.
31. Liu, H., Wu, R., Sun, Y., Ye, Y., Chen, J., Luo, X., Shen, X., Liu, H., Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease. Bioorg. Med. Chem. 22 (2014), 6344–6352.
32. Luo, D., Vasudevan, S.G., Lescar, J., The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Antivir. Res. 118 (2015), 148–158.
33. Malone, R.W., Homan, J., Callahan, M.V., Glasspool-Malone, J., Damodaran, L., Schneider Ade, B., Zimler, R., Talton, J., Cobb, R.R., Ruzic, I., Smith-Gagen, J., Janies, D., Wilson, J., Zika virus: medical countermeasure development challenges. PLoS Negl. Trop. Dis., 10, 2016, e0004530.
34. Mayor, S., Zika infection in pregnancy is linked to range of fetal abnormalities, data indicate. BMJ Clin. Res. Ed., 352, 2016, i1362.
35. Miranda-Filho Dde, B., Martelli, C.M., Ximenes, R.A., Araujo, T.V., Rocha, M.A., Ramos, R.C., Dhalia, R., Franca, R.F., Marques Junior, E.T., Rodrigues, L.C., Initial description of the presumed congenital Zika syndrome. Am. J. Public Health 106 (2016), 598–600.
36. Murshudov, G.N., Skubak, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., Winn, M.D., Long, F., Vagin, A.A., REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D. Biol. Crystallogr. 67 (2011), 355–367.
37. Noble, C.G., Seh, C.C., Chao, A.T., Shi, P.Y., Ligand-bound structures of the dengue virus protease reveal the active conformation. J. Virol. 86 (2012), 438–446.
38. Noble, C.G., Shi, P.Y., Structural biology of dengue virus enzymes: towards rational design of therapeutics. Antivir. Res. 96 (2012), 115–126.
39. Nowakowski, T.J., Pollen, A.A., Di Lullo, E., Sandoval-Espinosa, C., Bershteyn, M., Kriegstein, A.R., Expression analysis highlights AXL as a candidate Zika virus entry receptor in neural stem cells. Cell Stem Cell 18 (2016), 591–596.
40. Otwinowski, Z.M.W., Processing of X-ray diffraction data collected in oscillation mode. Method Enzymol. 276 (1997), 307–326.
41. Paixao, E.S., Barreto, F., da Gloria Teixeira, M., da Conceicao, N.C.M., Rodrigues, L.C., History, epidemiology, and clinical manifestations of Zika: a systematic review. Am. J. Public Health 106 (2016), 606–612.
42. Phoo, W.W., Li, Y., Zhang, Z., Lee, M.Y., Loh, Y.R., Tan, Y.B., Ng, E.Y., Lescar, J., Kang, C., Luo, D., Structure of the NS2B-NS3 protease from Zika virus after self-cleavage. Nat. Commun., 7, 2016, 13410.
43. Prusis, P., Junaid, M., Petrovska, R., Yahorava, S., Yahorau, A., Katzenmeier, G., Lapins, M., Wikberg, J.E., Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B-NS3 proteases. Biochem. Biophys. Res. Commun. 434 (2013), 767–772.
44. Robin, G., Chappell, K., Stoermer, M.J., Hu, S.H., Young, P.R., Fairlie, D.P., Martin, J.L., Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J. Mol. Biol. 385 (2009), 1568–1577.
45. Romano, K.P., Ali, A., Royer, W.E., Schiffer, C.A., Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 20986–20991.
46. Sampath, A., Padmanabhan, R., Molecular targets for flavivirus drug discovery. Antivir. Res. 81 (2009), 6–15.
47. Schrödinger, Epik, Version 3.5. Schrödinger. 2016.
48. Schrödinger, Ligprep, Version 3.7. Schrödinger. 2016.
49. Schrödinger, Schrödinger Suite 2016-1 Protein Preparation Wizard. 2016, LLC, New York, NY.
50. Shelley, J.C., Cholleti, A., Frye, L.L., Greenwood, J.R., Timlin, M.R., Uchimaya, M., Epik: a software program for pK( a ) prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 21 (2007), 681–691.
51. Sirohi, D., Chen, Z., Sun, L., Klose, T., Pierson, T.C., Rossmann, M.G., Kuhn, R.J., The 3.8 Å resolution cryo-EM structure of Zika virus. Science (New York, N.Y.), 352, 2016.
52. Smith, D.W., Mackenzie, J., Zika virus and Guillain-Barre syndrome: another viral cause to add to the list. Lancet (London, England), 387, 2016.
53. Tian, H., Ji, X., Yang, X., Zhang, Z., Lu, Z., Yang, K., Chen, C., Zhao, Q., Chi, H., Mu, Z., Xie, W., Wang, Z., Lou, H., Yang, H., Rao, Z., Structural basis of Zika virus helicase in recognizing its substrates. Protein Cell 7 (2016), 562–570.
54. Tomlinson, S.M., Watowich, S.J., Anthracene-based inhibitors of dengue virus NS2B-NS3 protease. Antivir. Res. 89 (2011), 127–135.
55. Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., Improved protein-ligand docking using GOLD. Proteins 52 (2003), 609–623.
56. Viswanathan, U., Tomlinson, S.M., Fonner, J.M., Mock, S.A., Watowich, S.J., Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery Web portal. J. Chem. Inf. Model. 54 (2014), 2816–2825.
57. Vogel, G., Infectious disease. Evidence grows for Zika virus as pregnancy danger. Science (New York, N.Y.) 351 (2016), 1123–1124.
58. Weaver, S.C., Costa, F., Garcia-Blanco, M.A., Ko, A.I., Ribeiro, G.S., Saade, G., Shi, P.Y., Vasilakis, N., Zika virus: history, emergence, biology, and prospects for control. Antivir. Res., 130, 2016.
59. Wise, J., Study links Zika virus to Guillain-Barre syndrome. BMJ Clin. Res. Ed., 352, 2016, i1242.
60. Wu, H., Bock, S., Snitko, M., Berger, T., Weidner, T., Holloway, S., Kanitz, M., Diederich, W.E., Steuber, H., Walter, C., Hofmann, D., Weissbrich, B., Spannaus, R., Acosta, E.G., Bartenschlager, R., Engels, B., Schirmeister, T., Bodem, J., Novel dengue virus NS2B/NS3 protease inhibitors. Antimicrob. Agents Chemother. 59 (2015), 1100–1109.
61. Xu, S., Li, H., Shao, X., Fan, C., Ericksen, B., Liu, J., Chi, C., Wang, C., Critical effect of peptide cyclization on the potency of peptide inhibitors against Dengue virus NS2B-NS3 protease. J. Med. Chem. 55 (2012), 6881–6887.
62. Yang, C.C., Hsieh, Y.C., Lee, S.J., Wu, S.H., Liao, C.L., Tsao, C.H., Chao, Y.S., Chern, J.H., Wu, C.P., Yueh, A., Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob. Agents Chemother. 55 (2011), 229–238.
63. Yang, C.C., Hu, H.S., Wu, R.H., Wu, S.H., Lee, S.J., Jiaang, W.T., Chern, J.H., Huang, Z.S., Wu, H.N., Chang, C.M., Yueh, A., A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease. Antimicrob. Agents Chemother. 58 (2014), 110–119.
64. Zhou, G.C., Weng, Z., Shao, X., Liu, F., Nie, X., Liu, J., Wang, D., Wang, C., Guo, K., Discovery and SAR studies of methionine-proline anilides as dengue virus NS2B-NS3 protease inhibitors. Bioorg. Med. Chem. Lett. 23 (2013), 6549–6554.